PQR514 (panPI3K/mTOR)

Indicaton

Dual PI3K/mTOR inhibitor with reduced brain penetration for use in oncology or other therapeutic areas.

Therapeutic indications

Oncology

Type of product

Small molecule

Table

Phase

Discovery

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal

Discovery